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Efficacy parameters were based on clinical trials: Jarnerot 2005, Sands 2001, 
Lichtiger 1994 and D'Haens 2001. Twelve-month time horizon was developed. 
Cost data specific for the Polish health care system was based on retrospective 
medical record review of patients with ulcerative colitis. Resource use associated 
with the surgery was based on clinical expert opinion. The unit costs of 
treatment were derived from Polish official tariff lists for health care services 
paid by public payer. Average body weight of the patient (60 kg) was based on 
data from registry of patients with Crohn’s disease, assuming the similar nature 
of the disease. RESULTS: Infliximab was associated with a gain of 0.21 quality 
adjusted life years (QALYs) compared with colectomy. Additional costs 
associated with the biological treatment were estimated at 14,793 PLN. 
Incremental cost-utility ratio was estimated at 69,984 PLN/QALY for infliximab 
compared with colectomy. The sensitivity analysis showed a relative consistency 
of results. CONCLUSIONS: The estimated cost per QALY is much below official 
threshold (99,543 PLN/QALY) which indicates that treatment with infliximab is 
cost effective compared with surgical treatment in Polish conditions.  
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COST-PER-NUMBER NEEDED TO TREAT (NNT) ANALYSIS OF INFLIXIMAB 
COMPARED TO ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE 
ULCERATIVE COLITIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS)  
Morais AD, Pereira ML 
Janssen Cilag Farmaceutica, São Paulo, Brazil  
OBJECTIVES: Compare the cost-per-remission of adalimumab (ADA) to 
infliximab (IFX) for the treatment of moderately to severely active ulcerative 
colitis (UC) in the Brazilian public health care system (SUS). METHODS: 
Treatment costs considered drug acquisition costs from a public payer 
perspective in Brazil considering an average patient of 80 kg. The cost/vial of IFX 
and ADA were defined by the latest government acquisitions, as published in the 
official website comprasnet.gov.br. The time horizon was defined at 8, 52 and 54 
weeks of treatment. The recommended dose and dosing intervals were 
according to label of each drug. The nnt was calculated based on the clinical 
remission data gathered at week 8 and week 52/54 from the published phase III 
clinical trials of ADA and IFX, ULTRA-2 and ACT I respectively. (Rutgeerts P 2005; 
Sandborn WJ 2012). RESULTS: At week 8, IFX has a treatment cost of R$ 13.652 
with a cost-per-NNT for clinical remission of R$ 54.610 (bio-naive and all 
patients), compared to ADA with a treatment cost of R$ 8.284 and a cost-per-NNT 
for clinical remission of R$ 115.983/patient and R$ 82.845/bio-naive patient. At 
week 52/54, IFX has a treatment cost of R$ 36.406 compared to ADA with R$ 
31.067/R$ R$ 32.102 per patient. Considering the cost-per-NNT for clinical 
remission at week 52/54, ADA has an average cost of R$ 341.735 compared to IFX 
with a cost-per-NNT for clinical remission of R$ 182.032 at week 52/54. 
Considering bio-naive patients, IFX remains with a cost-per-NNT for clinical 
remission of R$ 182.032 compared to ADA with R$ 310.668/R$ 341.735 at week 
52/54. CONCLUSIONS: IFX has a lower number needed to treat and a lower cost-
per-NNT to achieve clinical remission at both week 8 week 52/54 compared with 
ADA in the treatment of moderately to severely active ulcerative colitis, 
independently of patient subgroup.  
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COST EFFECTIVENESS ANALYSIS OF TENOFOVIR DISOPROXIL FUMARATE 
(VIREAD®) IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B 
(CHB) IN MEXICO  
Soto H1, Botello BS2, Pizarro M3, Rizzoli A4, Gozález LA2 
1Iteliness Consulting, D. F., Mexico, 2Iteliness Consulting, Mexico City, Mexico, 3Hospital Infantil 
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Mexico City, Mexico  
OBJECTIVES: To demonstrate the efficacy, security and effectiveness of tenofovir 
disoproxil fumarate (Viread®) in the treatment of patients with chronic hepatitis 
B (CHB) in Mexico, from the Mexican institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness of 5 competing 
strategies in CHB treatment, 1) tenofovir DF; 2) Entecavir; 3) Adefovir; 4) 
Lamivudine; and 5) Peginterferon alfa-2a, from the insititutional perspective. A 
Markov model was developed over 40 years’ time horizon. The outcome measure 
was the life years gained (LY). Direct health care cost where used and the 
discount rate was of 5% for cost and life years, also incremental cost 
effectiveness ratio (ICER), sensitivity analyses and probabilistic sensitivity 
analyses were performed. RESULTS: Tenofovir DF had more effectiveness and 
less cost in the treatment of CHB; in the Markov model tenofovir DF had the 
highest life years gained compared with all other therapies under evaluation. 
Tenofovir DF had 15.49LY with a cost of $363,314.84, Entecavir had 15.37LF with a 
cost of $435,849.99, Adefovir had 14.89LY with a cost of $487,457.55, Lamivudina 
had 13.84LY with a cost of $498,603.87 and Peginterferon alfa-2a had 13.56LY with 
a cost of $406,795.25, hence all the therapies had an ICER dominated by tenofovir 
DF in all the scenarios. The sensitivity analyses proved that tenofovir DF was 
cost effective compared to all other therapies under evaluation in the treatment 
of CHB patients in Mexico. According to the probabilistic sensitivity analyses, the 
likelihood of tenofovir DF to be cost effective is 88% under the willingness-to-pay 
threshold in Mexico. CONCLUSIONS: There is evidence from the clinical and the 
cost effectiveness study that the use of tenofovir DF in the treatment of patients 
with CHB is cost effective, and must be considered as first option in the 
treatment of patients with CHB diagnosis in Mexico.  
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THE VALUE OF IMPROVING TREATMENT ADHERENCE IN CHRONIC HEPATITIS C 
INFECTION  
McDermott CL, Veenstra DL, Hansen RN, Sullivan SD 
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WA, USA  
OBJECTIVES: In observational studies and randomized trials of patients with 
hepatitis C infection, higher medication adherence is associated with improved 
clinical outcomes. We evaluated the impact of adherence on long-term outcomes 
and costs in patients with genotype 1 chronic hepatitis C (CHC) receiving 
peginterferon and ribavirin (PEG-RBV). METHODS: We utilized a cohort Markov 
model describing the natural history of hepatitis C infection in a population of 50 
year-old, treatment-experienced subjects to evaluate transitions between CHC, 
compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver 
transplant, liver transplant survivor, and death. Using previously published data 
from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial, we 
modeled four levels of medication adherence: >80% PEG-RBV, >80% PEG/<80% 
RBV, <80% PEG/>80% RBV, and <80% PEG-RBV. We calculated the difference in 
total liver-related health care costs between patients in the lowest versus each 
higher level of adherence following a hypothetical nursing-based intervention 
program, and performed probabilistic sensitivity analysis to evaluate uncertainty 
in our results. RESULTS: Over a lifetime horizon, comparing patients of highest 
versus lowest adherence levels, we found the following reductions in liver-
related events: 9.9% compensated cirrhosis, 4.7% decompensated cirrhosis, 1.4% 
hepatocellular carcinoma, and 0.5% liver transplant. Among the various 
scenarios of medication adherence, the difference in total discounted treatment 
and medication costs ranged from $12,820 to $62,690. Thus, an intervention that 
could, on average, improve adherence by 20% would lead to cost offsets of $29, 
850 and improvement in QALYs of 0.378. The 95% confidence ranges from 
probabilistic sensitivity analysis were $18,790-$35,600 and -0.387 to 0.810 QALYs. 
CONCLUSIONS: This model-based analysis demonstrates that increased patient 
adherence may result in improved outcomes and reduced costs. Future research 
should focus on the design of targeted interventions to implement these 
findings.  
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(METEOSPASMYL®) IN THE TREATMENT OF PATIENTS WITH IBS IN  
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OBJECTIVES: To demonstrate the efficacy, security and effectiveness of 
alverine/simethicone (Meteospasmyl®) in the treatment of patients with irritable 
bowel syndrome (IBS) in Mexico, from institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness of 3 competing 
strategies in IBS treatment, 1) alverine/simethicone (A/S); 2) pinaverium bromide 
(PB); and 3) tegaserod (T). A decision tree was developed over 1 month time 
horizon, and then a Markov model was designed over 13 months, this model was 
carry out in two scenarios, the first Markov model studies the patient treatment 
only with one drug therapy, the second one analyses the patient using a switch 
of treatment if the patient didn’t respond to the first option. The outcome 
measure was the global improvement of the symptoms and the time without the 
disease respectively. Direct health care cost where used, also incremental cost 
effectiveness ratio (ICER), sensitivity analyses and probabilistic sensitivity 
analyses was performed. RESULTS: A/S had more effectiveness and less cost in 
the treatment of IBS; in the decision tree, for every 1% of patients with clinical 
response using A/S, it must be pay an average of $3048.15, in the Markov model 
A/S compared to PB was a dominant strategy; T was extended dominated in both 
analyses from the institutional perspective. The sensitivity analyses proved that 
A/S was cost effective compared to PB and T in the treatment of IBS patients in 
Mexico. According to the probabilistic sensitivity analyses, the likelihood of A/S 
to be cost effective is 90% under the willingness-to-pay threshold in Mexico. 
CONCLUSIONS: There is evidence from the clinical and the cost effectiveness 
study that the use of A/S in the treatment of patients with IBS is cost effective, 
and must be considered as first option in the treatment of patients with IBS 
diagnosis in Mexico.  
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COST-EFFECTIVE ANALYSIS OF DIAGNOSTIC APPROACHES FOR MONITORING 
ASYMPTOMATIC PANCREATIC NEOPLASMS  
Ptak DM1, Gricar J2, Pearlman DM3, Gardner T1, McKenna D1, Huang Y1 
1Dartmouth College, Hanover, NH, USA, 2Apo-Med, New York, NY, USA, 3Georgetown 
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OBJECTIVES: Recent advances in diagnostic imaging technology have been 
followed by an increased incidence of asymptomatic pancreatic neoplasms. 
Recommended clinical approaches to continued monitoring vary in frequency, 
invasiveness and cost. This study's objective is to compare the risks and cost 
implications associated with annual computed tomography (CT), empiricism 
(watchful waiting), endoscopic ultrasound (EUS) and magnetic resonance 
imaging (MRI) screening. METHODS: Cost and accuracy information was 
obtained from published peer-reviewed journal articles. Empiricism serves as a 
baseline comparison of these procedures and includes the cost of one annual 
physician visit. Incremental Cost Effectiveness Ratios (ICERs) were calculated, 
(procedure cost/detection rate accuracy) and compared across diagnostic testing 
procedures. Risk was defined as the chance of missed detection due to less 
accurate imaging or lack of screening. RESULTS: Costs for empiricism ($82) were 
minimal when compared to CT ($196), EUS ($671) and MRI ($363). Although 
empiricism was the least expensive monitoring strategy, it was associated with 
the highest risk of undetected metastasizings. Of the diagnostic options, CT had 
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the lowest diagnostic detection accuracy (74%), followed by MRI (80%) and EUS 
(94%). With CT as the baseline comparator, the ICERs for MRI ($2,783) and EUS 
($2,200) demonstrated that both were acceptable alternatives. CONCLUSIONS: 
Patients or physicians with low risk-tolerance are advised to avoid the watchful 
waiting approach. EUS, MRI and CT are all cost-effective diagnostic choices. 
Among the four choices, EUS is associated with the lowest risk and highest costs. 
EUS is the best monitoring choice when risk must be minimized irrespective of 
cost. Alternatively, annual MRI and CT scans may serve as a preferred option for 
patients and physicians aiming to balance risk-tolerance with procedure cost.  
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COST-EFFECTIVENESS OF RADIOFREQUENCY ABLATION COMPARED TO 
ENDOSCOPIC SURVEILLANCE FOR PATIENTS WITH BARRETT'S ESOPHAGUS 
WITH LOW GRADE DYSPLASIA  
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OBJECTIVES: Current guidelines for the management of patients with Barrett’s 
esophagus (BE) with high grade dysplasia recommend radiofrequency ablation 
(RFA) as a treatment, based upon demonstrated clinical and cost-effectiveness. 
For patients with BE with low grade dysplasia (LGD), in contrast, the mainstay of 
management is surveillance endoscopy. The aims of this study were to estimate 
whether RFA is cost-effective for patients with Barrett’s LGD compared to 
surveillance and to determine which factors influence the cost-effectiveness. 
METHODS: A cost-utility analysis was undertaken. A state transition Markov 
model was developed to estimate the costs and benefits of using RFA compared 
to surveillance in LGD. All direct medical costs were estimated from the 
perspective of the Australian health care system with adjustments for the US 
health care system. The model was run for the lifetime of the cohort of patients 
where quality of life differed by disease state. The incremental cost per quality 
adjusted life year (QALY) was estimated and uncertainty was explored using 
sensitivity analyses. RESULTS: Clinical evidence suggests that RFA is superior in 
treating LGD compared to surveillance. Replacing surveillance with RFA would 
yield an additional benefit of 0.129 QALYs. However the cost-effectiveness of RFA 
is highly uncertain. The main drivers of the cost-effectiveness results are the 
effectiveness of RFA, the probability of progression to cancer, and the cost of 
RFA. CONCLUSIONS: The available data suggest that active treatment with RFA 
provides significantly better clinical outcomes than surveillance, but the cost-
effectiveness of RFA in this patient group remains highly uncertain. RFA is not 
cost-effective if the low estimates of cancer risk for LGD from recent population-
based studies are used, but the accuracy of these estimates is unclear. Accurate 
estimates of the risk of developing cancer in patients with no dysplasia or LGD 
are needed to conduct valid and reliable cost-effectiveness analyses.  
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ASSESSMENT OF PRACTICE PATTERNS AND TREATMENT-FAILURE MEDICAL 
COSTS AMONG PATIENTS WITH CHRONIC CONSTIPATION: FINDINGS FROM A 
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OBJECTIVES: Chronic constipation (CC) is a common chronic functional 
gastrointestinal disorder that may be associated with increased utilization of 
health care resources. The objective of this study was to understand resource 
utilization and associated costs for patients with CC based on treatment 
response. METHODS: A web-based survey was conducted with a sample of 
primary care physicians (PCPs) and gastroenterologists (GEs) across different US 
regions. The survey captured data on referral patterns (to/from GEs), 
test/procedure ordering, and follow-up physician visits for typical patients who 
did and did not achieve satisfactory relief of symptoms to a recent treatment for 
CC (“response”). Survey items included questions regarding the proportion of 
patients who would receive tests/procedures and follow-up physician visits. 
Health care costs were estimated by applying associated unit costs (derived from 
the 2012 Medicare physician payment schedule) to the corresponding utilization. 
All patients were assumed to begin treatment with PCPs. Median and mean costs 
of treatment failure were calculated as the corresponding cost differences 
between physician-deemed non-responders and responders, incorporating both 
PCP work-up costs and the costs of referrals to GEs. RESULTS: Twenty PCPs and 
21 GEs completed the survey. These physicians treated a mean of 58 adults per 
month for CC. Most non-responders were referred to GEs by PCPs (median: 78%; 
mean: 68%). Non-responders were more likely to receive a test/procedure 
compared with responders (median: 90 vs. 0% for both PCPs and GEs; mean: 72 
vs. 5% for PCPs; 72 vs. 24% for GEs). Thyroid function tests and colonoscopy were 
the most common tests/procedures that would be ordered. Median (mean) 
expected cost of follow-up due to non-response was estimated to be $1,132 
($865). CONCLUSIONS: Patients with CC who do not respond satisfactorily to 
treatments are likely to require additional follow-up testing and referrals to 
specialists, potentially leading to increased health care costs.  
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Crawley JA1, Horowicz-Mehler N2, Hawryluk EA3, King F1 
1AstraZeneca Pharmaceuticals, Wilmington, DE, USA, 2Quintiles Global Consulting, New York, 
NY, USA, 3Quintiles Global Consulting, Hawthorne, NY, USA  
OBJECTIVES: Opioid-induced constipation (OIC) is a common gastrointestinal 
side effect of opioid treatment that can lead to alteration or discontinuation of 
opioid therapy. This multinational cross-sectional survey assessed OIC burden of 
illness. METHODS: Health care providers (HCPs) and a sample of their patients 
prescribed opioids for chronic noncancer pain were surveyed regarding patient 
laxative use, OIC symptoms, treatment patterns, and OIC impact on patient’s 
pain management/daily life. RESULTS: HCPs (n=63) and patients from Canada 
(n=64), France (n=60), Germany (n=60), the UK (n=60), and the United States 
(n=60) participated. Sixty-nine percent of patients were characterized as 
inadequate responders to laxative treatment (used laxatives on ≥4 days in past 
two weeks and had continued constipation symptoms or symptom resolution 
with laxative side effects). Inadequate responders were more likely to have 
started an opioid regimen in the last six months and to have ≤1 bowel movement 
(BM)/wk versus ≥2 compared with responders. The proportion of patients self-
reporting the following common gastrointestinal symptoms were higher than 
what physicians reported as the percent of their patients complaining of these 
symptoms: few normal or spontaneous BMs (88% vs 65%), hard lumpy stools 
(87% vs 71%), BMs different than normal (82% vs 59%), bloating (78% vs 71%), and 
abdominal discomfort/stomach cramps (75% vs 62%). Patients reported taking 
opioids less often (53%) or lowering the dose (57%) as a strategy to alleviate 
constipation, whereas HCPs reported recommending these strategies to 
approximately 10% of their patients with OIC. Approximately 40% of patients 
reported that constipation made it quite a bit harder or extremely harder to live 
with their chronic pain. CONCLUSIONS: Results indicate a disconnect in the 
frequency that OIC symptoms are experienced by patients versus perceived by 
their treating HCPs and also in the frequency of opioid dosing alteration to 
alleviate OIC by patients versus recommended by their HCPs.  
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Wu Y, King F 
AstraZeneca Pharmaceuticals, Wilmington, DE, USA  
OBJECTIVES: Constipation is the most common and often most debilitating  
side effect of opioid therapy for chronic pain. It has been reported that some 
patients rank constipation as a more common source of distress than their pain. 
Opioid-induced constipation (OIC) compounds the burden in these patients  
and may lead to opioid alterations in dosing regimen, discontinuation, 
inadequate pain management, and increased cost of care. METHODS: Using 
standard methodology, a targeted literature review was undertaken of studies 
published in the last 10 years (2002–2012) reporting quality of life (QOL) in 
patients with OIC receiving opioid therapy for cancer or noncancer pain. The 
review focused on PubMed (MEDLINE) and Embase; abstracts from recent key 
conferences/meetings for gastroenterology and pain were also reviewed. 
RESULTS: A limited number of publications (one review, four surveys, two small 
qualitative studies) were identified. While only the PAC-QOL has been validated 
in this population, various additional instruments were used to describe OIC 
impact on QOL, such as EQ-5D, the SF-8 questionnaire, a 5-point scale, an 11-
point scale, and qualitative descriptions. The burden of OIC on patient QOL was 
found to be considerable, with OIC patients experiencing worse QOL than 
patients without OIC in all four surveys. Of note, one survey showed that 
increasing severity of constipation correlated with decreasing QOL, while 
another indicated that patients with severe constipation were less satisfied with 
their pain treatment versus patients with mild, moderate, or no constipation. 
Mean satisfaction with pain treatment with no, mild, moderate and severe 
constipation was 6.6, 6.6, 6.2 and 5.2 (10-very satisfied). CONCLUSIONS: Current 
literature on the impact of OIC on QOL is very limited but consistently suggests 
that OIC adversely impacts QOL. More research is needed to fully quantify the 
impact on QOL and standardize research methodology. Alleviation of OIC may 
improve QOL and optimize pain management among these patients.  
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OBJECTIVES: To investigate the factors that potentially influence the UC 
patients’ anxiety and depression after having a colectomy utilizing patient 
survey tools. METHODS: A cross-sectional survey was administered online or via 
paper to patients ≥18 years of age with UC who had a colectomy surgery within 
the last 10 years in Canada, Australia, and the UK. Anxiety and depression was 
measured using the Hospital Anxiety and Depression Scale (HADS); scores > 8 on 
the respective anxiety and depression scales indicate the presence of the 
condition. Other scales used included the Inflammatory Bowel Disease 
Questionnaire (IBDQ), 5-item EuroQol (EQ-5D) questionnaire, Body Image 
Questionnaire (BIQ), Medical Outcomes Study Sexual Functioning Scale (MOS-
SFS), dietary restriction questions, and World Health Organization Health and 
Work Performance Questionnaire-Absenteeism and Presenteeism Questions 
(WHO-HPQ-AP). Logistic regression was used to investigate factors associated 
with anxiety. RESULTS: A total of 424 patients participated from Canada, UK, and 
Australia. Gender was equally distributed with a mean age of 42±13 years. 
Respondents were diagnosed with UC with a mean of 11.8±8.5 years ago and first 
